Solid Biosciences (SLDB) has an average rating of outperform and price targets ranging from $2 to $12, according to analysts polled by Capital IQ. (MT...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Solid Biosciences (SLDB) has an average rating of outperform and price targets ranging from $2 to $12, according to analysts polled by Capital IQ. (MT...
| Address | 500 Rutherford Avenue Charlestown, Massachusetts 02129 |
| Phone | +1.617.337.4680 |
| Number of Employees | 111 |
| Recent SEC Filing | 06/09/2022 4 |
| President, Chief Executive Officer & Director | Ilan Ganot |
| Chief Financial Officer & Treasurer | Stephen J. DiPalma |
| Chief Scientific Officer | Carl Morris |
| Senior VP, Head-Clinical Development | Roxana Donisa Dreghici |
| Price Open | $0.62 |
| Previous Close | $0.62 |
| 52 Week Range | $0.42 - 3.77 |
| Market Capitalization | $65.0 M |
| Shares Outstanding | 112.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/15/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.72 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -660.25% |
| Return on Equity | -37.71% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
